New Cisplatin Therapy Findings from Southern University of Science and Technology (SUSTech) Described (Parvb Deficiency Alleviates Cisplatin-induced Tubular Injury By Inhibiting Tak1 Signaling).

Předmět:	ALKYLATING agents PLATINUM compounds UBIQUITIN ligases NITROGEN compounds DRUG therapy CISPLATIN
Zdroj:	Drug Week; 12/6/2024, p1793-1793, 1p
Abstrakt:	A recent study conducted at the Southern University of Science and Technology in Shenzhen, China, explored the role of PARVB deficiency in alleviating cisplatin-induced renal tubular injury by inhibiting TAK1 signaling. The research found that depletion of PARVB in proximal tubular epithelial cells significantly reduced tubular cell death and inflammation caused by cisplatin. This study suggests that targeting the PARVB-TAK1 pathway could offer a novel therapeutic approach to mitigate cisplatin-induced kidney damage. [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu